Domperidone is NOT appropriate for treating simple abdominal bloating
Domperidone should not be used for bloating alone—it is specifically indicated for gastroparesis symptoms (nausea, vomiting, early satiety) and even then only as a non-first-line option. The most recent AGA guidelines make no mention of domperidone for bloating management, and explicitly recommend against its use as first-line therapy even for gastroparesis 1.
Why Domperidone is Wrong for Bloating
Bloating Management Does Not Include Prokinetics
The 2023 AGA Clinical Practice Update on bloating and distention provides comprehensive best practice advice without mentioning domperidone or any prokinetic agents 2. The recommended approach includes:
- Dietary modifications (low-FODMAP diet with dietitian supervision)
- Central neuromodulators (antidepressants for visceral hypersensitivity)
- Constipation-targeted therapies if constipation is present
- Psychological therapies (hypnotherapy, cognitive behavioral therapy)
- Biofeedback for pelvic floor disorders
- Diaphragmatic breathing for abdominophrenic dyssynergia
Notably, the guideline explicitly states that probiotics should NOT be used for bloating 2, and makes no recommendation for prokinetics of any kind.
Domperidone is for Gastroparesis, Not Bloating
The 2025 AGA gastroparesis guidelines position domperidone as a conditional recommendation AGAINST first-line use even for its intended indication 1. It targets nausea, vomiting, and early satiety—not bloating. The mechanism is purely prokinetic through dopamine D2 receptor antagonism, which addresses delayed gastric emptying, not the pathophysiology of bloating (which involves visceral hypersensitivity, gas handling abnormalities, and abdominophrenic dyssynergia).
Significant Safety Concerns
Cardiac Risks
Even in the absence of cardiac disease or QT-prolonging medications, domperidone carries meaningful risks:
- QT prolongation occurs in 6-24% of patients at standard doses (30-80 mg/day) 3
- Increased risk of ventricular arrhythmias and sudden cardiac death with OR 1.59-11.02 in population studies 4
- Risk increases significantly in patients >60 years or doses >30 mg/day 4
- Mandatory cardiac monitoring required: baseline ECG, potassium, magnesium, and ongoing monitoring 1
Regulatory Status
- Not FDA-approved for human use in the United States 1, 5
- Requires expanded access IND application from FDA 1
- Current supplier exiting the market, making access increasingly difficult 1
Drug Interactions
Domperidone is a P-glycoprotein substrate metabolized via CYP3A4 5. Co-administration with CYP3A4 inhibitors (erythromycin, ketoconazole, many others) causes multi-fold increases in drug exposure 5, 6, dramatically increasing cardiac risk.
Common Pitfall to Avoid
Do not conflate upper GI symptoms. Bloating is distinct from gastroparesis symptoms. While both may coexist in disorders of gut-brain interaction, the treatment algorithms differ completely. Using a high-risk, difficult-to-obtain medication with cardiac monitoring requirements for a symptom it doesn't target represents poor clinical judgment.
The Correct Approach for Bloating
Start with the evidence-based algorithm from the 2023 AGA guidelines 2:
- Rule out organic disease if alarm features present (imaging, endoscopy only if indicated)
- Dietary intervention with gastroenterology dietitian (low-FODMAP trial)
- Treat constipation if present (consider anorectal physiology testing for pelvic floor disorders)
- Central neuromodulators (tricyclic antidepressants or SSRIs) for visceral hypersensitivity
- Brain-gut behavioral therapies (hypnotherapy, CBT)
If gastroparesis is actually suspected (nausea, vomiting, early satiety, documented delayed gastric emptying), then metoclopramide or erythromycin are the appropriate first-line options 1—not domperidone.